Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...
The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...
Clinical Trials Arena on MSN3d
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setbackThe pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...
Solengepras, the most advanced investigational treatment in Cerevance's pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson's disease. A brain-penetrant, specific ...
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...
Takeda and venture capital group Lightstone Ventures have launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback